203 related articles for article (PubMed ID: 35411251)
21. Development of molecularly targeted agents and immunotherapies in small cell lung cancer.
Sharp A; Bhosle J; Abdelraouf F; Popat S; O'Brien M; Yap TA
Eur J Cancer; 2016 Jun; 60():26-39. PubMed ID: 27060747
[TBL] [Abstract][Full Text] [Related]
22. Small-cell lung carcinoma: inhibition of proliferation by vasoactive intestinal peptide and helodermin and enhancement of inhibition by anti-bombesin antibody.
Maruno K; Said SI
Life Sci; 1993; 52(24):PL267-71. PubMed ID: 8389407
[TBL] [Abstract][Full Text] [Related]
23. [Small cell lung cancer--state of the art and future perspectives].
J Barata F; Costa AF
Rev Port Pneumol; 2007; 13(4):587-604. PubMed ID: 17898914
[TBL] [Abstract][Full Text] [Related]
24. Advances in antibody therapeutics targeting small-cell lung cancer.
Lu H; Jiang Z
Adv Clin Exp Med; 2018 Sep; 27(9):1317-1323. PubMed ID: 29790694
[TBL] [Abstract][Full Text] [Related]
25. Study of small-cell lung cancer cell-based sensor and its applications in chemotherapy effects rapid evaluation for anticancer drugs.
Guohua H; Hongyang L; Zhiming J; Danhua Z; Haifang W
Biosens Bioelectron; 2017 Nov; 97():184-195. PubMed ID: 28599178
[TBL] [Abstract][Full Text] [Related]
26. Management of small-cell lung cancer: incremental changes but hope for the future.
Hann CL; Rudin CM
Oncology (Williston Park); 2008 Nov; 22(13):1486-92. PubMed ID: 19133604
[TBL] [Abstract][Full Text] [Related]
27. Update 2021: Management of Small Cell Lung Cancer.
Tariq S; Kim SY; Monteiro de Oliveira Novaes J; Cheng H
Lung; 2021 Dec; 199(6):579-587. PubMed ID: 34757446
[TBL] [Abstract][Full Text] [Related]
28. Surgery for limited-stage small-cell lung cancer.
Barnes H; See K; Barnett S; Manser R
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011917. PubMed ID: 28429473
[TBL] [Abstract][Full Text] [Related]
29. Small Cell Lung Cancer.
Kalemkerian GP
Semin Respir Crit Care Med; 2016 Oct; 37(5):783-796. PubMed ID: 27732999
[TBL] [Abstract][Full Text] [Related]
30. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy.
Nagy A; Schally AV
Curr Pharm Des; 2005; 11(9):1167-80. PubMed ID: 15853664
[TBL] [Abstract][Full Text] [Related]
31. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes.
Zhou J; Chen J; Zhong R; Mokotoff M; Shultz LD; Ball ED
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2224-31. PubMed ID: 16609038
[TBL] [Abstract][Full Text] [Related]
32. Lung Cancer-Targeting Peptides with Multi-subtype Indication for Combinational Drug Delivery and Molecular Imaging.
Chi YH; Hsiao JK; Lin MH; Chang C; Lan CH; Wu HC
Theranostics; 2017; 7(6):1612-1632. PubMed ID: 28529640
[TBL] [Abstract][Full Text] [Related]
33. A correlation of bombesin-responsiveness with myc-family gene expression in small cell lung carcinoma cell lines.
Sausville EA; Moyer JD; Heikkila R; Neckers LM; Trepel JB
Ann N Y Acad Sci; 1988; 547():310-21. PubMed ID: 2467598
[TBL] [Abstract][Full Text] [Related]
34. Novel therapies in small cell lung cancer.
Mamdani H; Induru R; Jalal SI
Transl Lung Cancer Res; 2015 Oct; 4(5):533-44. PubMed ID: 26629422
[TBL] [Abstract][Full Text] [Related]
35. Etoposide plus cisplatin chemotherapy improves the efficacy and safety of small cell lung cancer.
Wang Z; Mai S; Lv P; Xu L; Wang Y
Am J Transl Res; 2021; 13(11):12825-12833. PubMed ID: 34956497
[TBL] [Abstract][Full Text] [Related]
36. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
Ann Oncol; 1997 Jan; 8(1):49-56. PubMed ID: 9093707
[TBL] [Abstract][Full Text] [Related]
37. Small cell lung cancer; recent advances of its biology and therapeutic perspective.
Hayashi R; Inomata M
Respir Investig; 2022 Mar; 60(2):197-204. PubMed ID: 34896039
[TBL] [Abstract][Full Text] [Related]
38. Small-cell Lung Cancer in Very Elderly (≥ 80 Years) Patients.
Schild SE; Zhao L; Wampfler JA; Daniels TB; Sio T; Ross HJ; Paripati H; Marks RS; Yi J; Liu H; He Y; Yang P
Clin Lung Cancer; 2019 Jul; 20(4):313-321. PubMed ID: 31155475
[TBL] [Abstract][Full Text] [Related]
39. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
Garst J; Herndon JE; Shafman T; Campagna L; Blackwell S; Padilla K; Bjurstrom T; Andrews C; Maravich-May D; Anderson E; Crawford J
Clin Drug Investig; 2006; 26(5):257-66. PubMed ID: 17163259
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Small Cell Lung Cancer.
Horiike A; Saijo N
Cancer Res Treat; 2003 Jun; 35(3):177-80. PubMed ID: 26680934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
